Completed

SAHHEARTCardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
DNA Samples
Who is being recruted

Brain Diseases+8

+ Cardiovascular Diseases

+ Central Nervous System Diseases

Over 18 Years
+7 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: February 2012
See protocol details

Summary

Principal SponsorKuopio University Hospital
Last updated: March 15, 2018
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2012

Actual date on which the first participant was enrolled.

Laboratory markers daily: Routine laboratory test (blood gases, haemoglobin, thrombocytes, leukocytes, INR, bilirubin, creatinine, c-reactive protein, CK, CK-MB, Tnt, BNP, sodium, potassium, magnesium) are taken at 8 a.m. Study laboratory tests (sensitive ischemia markers, remodelling marker MMP-9 and CgA as surrogate marker for increased sympathetic activity) are taken four times during study period at the same time as cardiac ECHOes and Holtering. Gene sample is taken once on day one. Primary outcome measurement is to document the incidence of myocardial dysfunction and the predictive factors during the hospital stay and at three months. Secondary outcome is to assess the impact of cardiac problems on morbidity and mortality during first three months.

Principal SponsorKuopio University Hospital
Last updated: March 15, 2018
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

198 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Brain DiseasesCardiovascular DiseasesCentral Nervous System DiseasesCerebrovascular DisordersHemorrhageNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsVascular DiseasesIntracranial HemorrhagesSubarachnoid Hemorrhage

Criteria

3 inclusion criteria required to participate
Age > 18 years

Aneurysmal bleeding

Patients with nontraumatic subarachnoid haemorrhage

4 exclusion criteria prevent from participating
Age < 18 years

Anticipated brain death < 24 hours

No consent

Otherwise moribund patient

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

Kuopio University Hospital

Kuopio, FinlandOpen Kuopio University Hospital in Google Maps

Turku University Hospital

Turku, Finland

Inselspital Bern

Bern, Switzerland
Completed3 Study Centers